54 completed. 54 Phase 1, 23 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 54 | Completed 54 |
| Phase 2 | 23 | Completed 23 |
Follow Bendamustine: new trials by email Literature Review of Bendamustine trials Research Report on Bendamustine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) FT522, Rituximab, Cyclophosphamide - Relapsed/Refractory B-Cell Lymphoma | Phase 1 | Completed | Fate Therapeutics | 20 | 2023-11-16 | 2025-08-22 |
| FT576 in Subjects With Multiple Myeloma FT576 (Allogenic CAR NK cells with BCMA expression), Cyclophosphamide, Fludarabine - Multiple Myeloma, Myeloma | Phase 1 | Completed | Fate Therapeutics | 31 | 2021-11-10 | 2025-12-12 |
| AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma AB-101, Rituximab, Interleukin-2 - Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Artiva Biotherapeutics, Inc. | 45 | 2021-03-29 | 2026-04-03 |
| A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma CC-95266, Fludarabine, Cyclophosphamide - Multiple Myeloma | Phase 1 | Completed | Juno Therapeutics, a Subsidiary of Celgene | 130 | 2021-02-24 | 2026-02-09 |
| Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Bendamustine, Gemcitabine, Nivolumab - Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Emory University | 3 | 2018-11-26 | 2025-08-06 |
| Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL Total Body Irradiation, Haploidentical Stem Cell Transplantation, CD56-Enriched Donor Lymphocyte Infusion - Multiple Myeloma, CLL | Phase 1 | Completed | Noah Merin | 20 | 2018-07-18 | 2024-11-12 |
| INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) Parsaclisib, Rituximab, Bendamustine - B-cell Lymphoma | Phase 1 | Completed | Incyte Corporation | 50 | 2018-07-02 | 2025-08-21 |
| Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma Rituximab, Bendamustine, Vincristine sulfate liposome injection - Lymphoma, Non-Hodgkin, Lymphoma, Follicular | Phase 1 | Completed | Brown University | 11 | 2017-05-10 | 2023-02-09 |
| Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) Parsaclisib, Hexal, Gazyvaro - Lymphoma | Phase 1 | Completed | Incyte Corporation | 26 | 2017-02-15 | 2025-08-21 |
| Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine Bendamustine, Cyclophosphamide - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia | Phase 1 | Completed | University of Arizona | 50 | 2016-11-29 | 2025-11-10 |
| GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia Allogeneic stem cell transplantation, Fludarabine monophosphate, Busulfan - Leukemia, Acute Lymphoblastic, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | St. Petersburg State Pavlov Medical University | 27 | 2016-06-01 | 2020-11-23 |
| A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia Durvalumab, Lenalidomide, Rituximab - Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 / Phase 2 | Completed | Celgene | 106 | 2016-05-11 | 2023-11-18 |
| Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma Bendamustine, Rituximab, Cytarabine - Mantle Cell Lymphoma | Phase 1 | Completed | Washington University School of Medicine | 18 | 2016-04-18 | 2023-11-01 |
| Hodgkin Lymphoma Treatment With Adcetris and Levact in the Old Patient Adcetris-Levact - Clinical Efficacy, Safety | Phase 1 / Phase 2 | Completed | Centre Antoine Lacassagne | 60 | 2016-01-14 | 2026-08-31 |
| A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) Atezolizumab, Bendamustine, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Lymphoma Follicular | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 91 | 2015-12-22 | 2021-05-24 |
| Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Carfilzomib, Bendamustine, Rituximab - Lymphoma, Non-Hodgkin, Lymphoma | Phase 1 | Completed | University of California, San Francisco | 10 | 2015-05-05 | 2021-04-23 |
| Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide - Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Kite, A Gilead Company | 307 | 2015-04-21 | 2024-06-04 |
| A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma Bendamustine, Obinutuzumab, Polatuzumab vedotin (Liquid) - Lymphoma | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 331 | 2014-10-15 | 2022-11-14 |
| A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas CD133+ selected autologous stem cell infusion, IL-2, hu14.18K322A - Neuroblastoma, Lymphoma | Phase 1 | Completed | St. Jude Children's Research Hospital | 8 | 2014-10-10 | 2017-12-22 |
| Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer everolimus, bendamustine hydrochloride - Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma | Phase 1 | Completed | University of California, Davis | 20 | 2014-10-01 | 2019-01-04 |
Showing 20 of 54. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (16) · Lymphoma, Non-Hodgkin (15) · Lymphoma (13) · Hodgkin Disease (11) · Lymphoma, Follicular (10) · Lymphoma, Mantle-Cell (8) · Multiple Myeloma (7) · Lymphoma, B-Cell, Marginal Zone (6) · Lymphoma, Large B-Cell, Diffuse (6) · Leukemia (4) · Lymphoma, B-Cell (4) · Recurrence (4) · Neoplasms (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Breast Neoplasms (2)
Hoffmann-La Roche (3) · M.D. Anderson Cancer Center (3) · Aptevo Therapeutics (2) · Cephalon (2) · Fate Therapeutics (2) · Genentech, Inc. (2) · Incyte Corporation (2) · St. Jude Children's Research Hospital (2) · Weill Medical College of Cornell University (2) · AbbVie (1) · Alliance for Clinical Trials in Oncology (1) · Arbeitsgemeinschaft medikamentoese Tumortherapie (1) · Artiva Biotherapeutics, Inc. (1) · Beth Christian (1) · Brown University (1)
United States (47) · France (6) · Germany (6) · Italy (6) · Spain (5) · Australia (4) · Canada (4) · Netherlands (4) · United Kingdom (3) · Austria (2) · Czechia (2) · Hungary (2) · Israel (2) · Poland (2) · Russia (2)
Scott Stromatt, MD (2) · Adam J Olszewski, MD (1) · Alexey V Danilov, MD (1) · Apostolia M. Tsimberidou, MD, PhD (1) · Beth Christian, MD (1) · Boris V. Afanasyev, Professor (1) · Brad S Kahl, M.D. (1) · Brandon M. Triplett, MD (1) · Charalambos Andreadis, M.D. (1) · Emmanuel Katsanis, MD (1)
PMID 19860608, PMID 21816833, PMID 22451423, PMID 23430121, PMID 23843495, PMID 25145344, PMID 25769620, PMID 26331432, PMID 26659915, PMID 28011903, PMID 29226797, PMID 29276022, PMID 29296805, PMID 29703778, PMID 29908231, PMID 30518502, PMID 31050355, PMID 31190006, PMID 31693429, PMID 31723767, PMID 32126141, PMID 32582591, PMID 32705923, PMID 32770353, PMID 33028076, PMID 33035333, PMID 33334730, PMID 33478921, PMID 33586581, PMID 33598942, PMID 34296427, PMID 34310745, PMID 34493319, PMID 34515338, PMID 34749395, PMID 35086141, PMID 35359000, PMID 35460929, PMID 35641232, PMID 35847727, PMID 35852004, PMID 36287231, PMID 36821768, PMID 37981564, PMID 38598516, PMID 38635762, PMID 38843483, PMID 39240498, PMID 40270968, PMID 42233419
2015 (3), 2008 (1), 2014 (1), 2016 (1), 2017 (1), K12CA076930 (1), P30CA012197 (1), P30CA016672 (1), P30CA023108 (1), P30CA138292 (1)